Product Benefits

• Primary Biliary Cholangitis (PBC) Management: Obeliva 5mg is specifically designed as the initial treatment for adults with PBC, either in combination with UDCA or as a standalone therapy for those who cannot tolerate UDCA.

• Optimal Starting Dose: The 5mg strength allows doctors to safely initiate therapy and monitor the patient's liver response before considering a dose increase, minimizing potential side effects like itching.

• Regulates Bile Acid Synthesis: It acts as a Farnesoid X Receptor (FXR) agonist, effectively reducing the liver's production of bile acids, which prevents toxic buildup that damages liver tissue.

• Lowers Alkaline Phosphatase (ALP): Clinical studies show significant reduction in ALP levels, a primary biomarker used to track the progression and severity of liver disease.

• Protects Bile Ducts: By improving bile flow and reducing inflammation, it helps protect the small bile ducts within the liver from autoimmune-mediated destruction.

• Slows Disease Progression: Long-term use of Obeticholic Acid helps delay the progression toward liver fibrosis, cirrhosis, and the eventual need for a liver transplant.

• Specialized Liver Care: Provides a breakthrough medical option for "non-responders" to traditional liver medications, offering a new path to managing chronic cholestatic liver conditions.